ArticleFrontiers in immunology2021
Melatonin Mitigates Oxazolone-Induced Colitis in Microbiota-Dependent Manner.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Melatonin Alleviated Cadmium Induced Microbiota-Gut-Brain Disorder in Adult Zebrafish: Insights from Transcriptomic and Microbiome Analysis.Biological trace element research · 2026Article
- Disturbed LTB4 Metabolism in ILC2s Aggravates Ulcerative Colitis via Intercellular ATP Accumulation.Inflammation · 2026Article
- Melatonin suppresses ILC2-driven airway hyperreactivity via glutathione-dependent metabolic reprogramming.Frontiers in immunology · 2026Article
- Melatonin: a promising therapy to combat type 2 airway inflammation via MT1-Sirt1 pathway.Frontiers in pharmacology · 2026Article
- The melatonin-microbiome axis: a new frontier in gut health for the immunomodulatory, antioxidant and anti-inflammatory properties.Inflammopharmacology · 2026Review
- Colon-targeted oral delivery of melatonin for regulating macrophage activity and intestinal barrier in ulcerative colitis.Theranostics · 2026Article
- Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications.Journal of pineal research · 2026Review
- Study on the anti-inflammatory effects and mechanisms of gentisic acid based on the LPS-induced RAW264.7 cell inflammation model and the oxazolone-induced zebrafish inflammation model.Frontiers in pharmacology · 2026Article
- Melatonin alleviates diarrhea and visceral hypersensitivity in rats with diarrhea-predominant irritable bowel syndrome by modulating of the TLR4/MyD88/NF-κB pathway.BMC gastroenterology · 2025Article
- CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast Cancer.International journal of molecular sciences · 2025Article
- Human calculus adhesive-induced periodontitis model recapitulating human periodontitis microbiota in rats.BMC oral health · 2025Article
- Assessing the relationship between the gut microbiota and growth traits in Chinese indigenous pig breeds.BMC veterinary research · 2025Article
- Melatonin Sources in Sheep Rumen and Its Role in Reproductive Physiology.Animals : an open access journal from MDPI · 2024Article
- Microbial melatonin metabolism in the human intestine as a therapeutic target for dysbiosis and rhythm disorders.NPJ biofilms and microbiomes · 2024Review
- The Effect Mechanism of N6-adenosine Methylation (m6A) in Melatonin Regulated LPS-induced Colon Inflammation.International journal of biological sciences · 2024Article
- Melatonin as a Mediator of the Gut Microbiota-Host Interaction: Implications for Health and Disease.Antioxidants (Basel, Switzerland) · 2023Review
- Effects of EnterotoxigenicMicroorganisms · 2023Article
- Circadian rhythms and inflammatory diseases of the liver and gut.Liver research (Beijing, China) · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levels of type 2 cytokines are elevated in the blood and intestinal tissues of ulcerative colitis (UC) patients in the active phase; this phenomenon indicates the participation of type 2 immune response in UC progression. The beneficial effects of melatonin in dextran sodium sulfate (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) colitis models have been illustrated, but its role in the oxazolone (Oxa)-induced colitis model (driven by type 2 immune response) remains relatively unknown. We investigated the relationship between melatonin concentration and the severity of UC, revealing a significantly negative correlation. Subsequently, we investigated the effects of melatonin in Oxa-induced colitis mice and the potential underlying mechanisms. Administration of melatonin significantly counteracted body weight loss, colon shortening, and neutrophil infiltration in Oxa-induced colitis mice. Melatonin treatment mitigated Oxa-induced colitis by suppressing type 2 immune response. In addition, melatonin attenuated intestinal permeability by enhancing the expression of ZO-1 and occludin in colitis mice. Interestingly, the protective effect of melatonin was abolished when the mice were co-housed, indicating that the regulation of gut microbiota by melatonin was critical in alleviating Oxa-induced colitis. Subsequently, 16S rRNA sequencing was performed to explore the microbiota composition. Decreased richness and diversity of intestinal microbiota at the operational taxonomic unit (OTU) level resulted from melatonin treatment. Melatonin also elevated the abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.